MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Q2 FY23 Earnings Conference Call held on November 16, 2022.21-11-2022
21-11-2022
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Please find attached daily report pursuant to Regulation 18 of Buyback Regulations17-11-2022
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the Q2FY23 & H1FY23 Results Conference Call is hosted on the website of the Company under the following link: http://marksanspharma.com/investors-meet.htmI16-11-2022
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith extract of unaudited financial results of the Company for the quarter and half-year ended September 30, 2022 published on November 16, 2022 in the Business Standard (English) and Lakshadeep (Marathi) newspapers.16-11-2022
MARKSANS PHARMA LTD. - 524404 - Appointment Of Internal Auditor
This is to inform you that based on the recommendation of Audit Committee, the Board of Directors of the Company at its Meeting held on 14thNovember, 2022 has approved the appointment of M/s. JVJ & Co., Chartered Accountants firm (Firm Registration No: 141427W) as the Internal Auditor of the Company, in accordance with the provision of Section 138 of the Companies Act, 2013 read with rules made thereto. The details as required under Regulation 30SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015read with SEBI Circular CIR/CFD/CMD/4/2015 are enclosed as Annexure-I.15-11-2022
Q2FY23 Quarterly Result Announced for Marksans Pharma Ltd.
Marksans Pharma announced Q2FY23 results : Q2FY23: Operating revenue at Rs 452.6 crore, increased 25.5% YoY driven by strong underlying volume growth in existing products as well as market share gains US growth was 13.7% YoY, despite the price erosion of high single digits in the Generic Rx business UK and Europe growth was 32.6% YoY led by volume growth and market share gains in the existing portfolio Australia and NZ grew by 39% YoY while the rest of the world was up by 56.4% YoY Gross profit at Rs 229.4 crore, increased 23.4% YoY with gross margins at 50.7% EBITDA at Rs 80.3 crore, increased 33.6% YoY, with EBITDA margins at 17.7% R&D; spend at Rs 9.8 crore. was 2.2% of sales H1FY23: Operating revenue at Rs 886.3 crore, increased by 24.8% YoY Gross profit at Rs 448.3 crore, grew by 20.4% YoY with gross margins at 50.6% EBITDA at Rs 153.1 crore, increased 11.4% YoY with EBITDA margins at 17.3% Cash balance stood at a healthy Rs 335 crore as on September 30, 2022 Mark Saldanha, Managing Director of the company, said, "We saw high double-digit growth with robust performance across all our regions, despite a tough operating environment, as we continued investing in our capabilities. Manufacturing and Innovation are our strategic pillars, and we believe the acquisition of capacity from Tevapharm India will provide further fillip to growth. We continue to navigate the challenging environment through our strong execution. Looking ahead, we continue to see growing demand in our OTC segment across the regions, and we are well-positioned to take advantage of these opportunities." Result PDF15-11-2022
MARKSANS PHARMA LTD. - 524404 - Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDl/162/2019 dated December 24, 2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021. Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended 30th September, 2022 is given in "Annexure A".14-11-2022
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release dated 14th November, 2022 titled Q2FY23 and H1FY23 Financial Results14-11-2022
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation H1FY23 & Q2FY2314-11-2022
MARKSANS PHARMA LTD. - 524404 - Unaudited Financial Results For The Quarter And Half-Year Ended 30Th September, 2022 And Limited Review Report Thereon.
In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the quarter and half-year ended 30th September, 2022 which have been approved by the Board of Directors at its meeting held today i.e. 14th November, 2022 along with Limited Review Reports given by statutory auditor of the Company. The meeting commenced at 06:45 p.m. and concluded at 07:45 p.m.14-11-2022